Organogenesis
Develops regenerative products for advanced wound care, surgery, and sports medicine.
$1.74
After-hours close+0.00 (+0.29%)
At close$1.74(−0.29%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 48.25%62.09M sharesInsiders 10.15%13.06M sharesOther 41.60%53.53M shares
Shares outstanding 128.67M · Float 57.38M · 44.6% free float
Institutions13F, as of Mar 31, 2026
121 holders · 62.09M shares · 16 new positions · 53 increased · 46 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 11.62M | 9.03% | −22.0K | May 15, 2026 |
| Soleus Capital Management, L.P. | 10.09M | 7.84% | +100.0K | May 14, 2026 |
| BlackRock, Inc. | 4.90M | 3.81% | +138.7K | May 13, 2026 |
| First Light Asset Management, LLC | 3.50M | 2.72% | −364.3K | May 15, 2026 |
| Vanguard Capital Management LLC | 2.90M | 2.25% | +2.90Mnew | May 15, 2026 |
| Dimensional Fund Advisors LP | 2.89M | 2.25% | +160.0K | May 7, 2026 |
| D. E. Shaw & Co., Inc. | 2.30M | 1.79% | +309.5K | May 15, 2026 |
| Assenagon Asset Management S.A. | 1.97M | 1.53% | −3.57M | Apr 20, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Thompson Deanincl. David Burgstahler, Avista Healthcare Partners III, L.P. +3 more | 18.00% | 28.68M | 13D | Nov 19, 2024 ↗ |
| Alan A. Adesincl. GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, GN 2016 Family Trust u/a/d August 12, 2016 +11 more | 17.60% | 22.32M | 13D | Jun 26, 2025 ↗ |
| Glenn H. Nussdorfincl. GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, GN 2016 Family Trust u/a/d August 12, 2016 | 9.70% | 12.25M | 13D | Nov 3, 2025 ↗ |
| Soleus Capital Master Fund, L.P. | 7.90% | 9.99M | 13G | Feb 12, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Gary S. Gillheeney | director, officer: President and CEO | 4.23M | 3.29% | Mar 3, 2026 |
| Glenn H. Nussdorf | director | 2.90M | 2.25% | Dec 18, 2025 |
| Patrick Bilbo | officer: Chief Operating Officer | 1.13M | 0.88% | Mar 3, 2026 |
| Lori Freedman | officer: Chief Admin. and Legal Officer | 1.02M | 0.80% | Mar 3, 2026 |
| Brian Grow | officer: Chief Commercial Officer | 900.7K | 0.70% | Apr 24, 2026 |
| David Francisco | officer: Chief Financial Officer | 731.3K | 0.57% | Mar 3, 2026 |
| Arthur S. Leibowitz | director | 291.0K | 0.23% | Mar 11, 2026 |
| Robert Cavorsi | officer: Vice President, Strategy | 275.5K | 0.21% | Mar 3, 2026 |
| Prathyusha Duraibabu | director | 247.0K | 0.19% | Feb 20, 2026 |
| Jon L. Giacomin | director | 241.0K | 0.19% | Feb 20, 2026 |
8 ten-percent owners hold 343.69M shares by Form 4, outside the officers-and-directors figure above · 19 people have not refiled in the last 18 months (250.10M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph Driscolldirector | Purchase | 10,000 | $2.67 | 225,707 |
| Mar 9, 2026 | Arthur S. Leibowitzdirector | Purchase | 5,000 | $2.68 | 291,014 |
| Dec 16, 2025 | Glenn H. Nussdorfdirector | Sale | 200,000 | $5.14 | 2,565,591 |
| Nov 26, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 187,957 | $5.29 | 2,765,591 |
| Nov 25, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 12,043 | $5.30 | 2,953,548 |
| Nov 24, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 100,000 | $5.34 | 2,965,591 |
| May 14, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Purchase | 251,001 | $3.09 | 251,001 |
| Jun 10, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 18,620 | $3.56 | 335,719 |
| Jun 9, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Sale | 4,156 | $3.50 | 354,339 |
| May 15, 2025 | Glenn H. Nussdorfdirector, 10 percent owner: | Purchase | 107,494 | $2.99 | 358,495 |
CongressHouse and Senate disclosures
Not reported.